Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 22 December 2006:
Vol. 314. no. 5807, p. 1837
DOI: 10.1126/science.314.5807.1837l
Prev | Table of Contents | Next

This Week in Science

After vaccination, the efficiency with which protective antibodies are produced often depends on the presence of an adjuvant, a substance that promotes activation of antibody-producing B cells. It has been anticipated that Toll-like receptors (TLRs) might be major players in mediating the effects of adjuvants. However, Gavin et al. (p. 1936; see the news story by Wickelgren) now find that the known TLR pathways do not modulate B cell responses and so adjuvants containing TLR ligands must depend on other properties. Such a revision to thinking about the effects of TLR on B cell responses will likely refocus current thinking about vaccine development.




To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)